5-anilino-2-hydroxy-benzoic acid | 107625-01-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-anilino-2-hydroxy-benzoic acid
• 英文别名: 5-Anilino-2-hydroxy-benzoesaeure；4-Oxy-diphenylamin-carbonsaeure-(3)；5-Anilino-salicylsaeure；5-Anilino-2-hydroxybenzoic acid
• CAS: 107625-01-4
• 化学式: C₁₃H₁₁NO₃
• 分子量: 229.235
• InChiKey: UAKRPAUMWBYMIY-UHFFFAOYSA-N

物化性质

• 沸点：
  409.5±35.0 °C(Predicted)
• 密度：
  1.377±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  methylammonium carbonate 、 alkaline earth salt of/the/ methylsulfuric acid 170.0 ℃ 、980.59 kPa 条件下， 生成 5-anilino-2-hydroxy-benzoic acid
  参考文献：
  名称：

  DE513211

  摘要：

  公开号：

文献信息

• Methods and compositions employing 4-aminophenylacetic acid compounds
  申请人：Ekwuribe N. Nnochiri

  公开号：US20070060552A1

  公开（公告）日：2007-03-15

  The invention provides compositions comprising 4-APAA compounds and methods for treating disorders involving inflammation of the digestive system and/or mucosal tissues, such as inflammatory bowel disease. The methods and compositions of the invention also include combinations of 4-APAA compounds and 5-ASA compounds for treatment of such disorders.

  本发明提供了包含4-APAA化合物的组合物以及治疗涉及消化系统和/或黏膜组织炎症的疾病的方法，例如炎性肠病。本发明的方法和组合物还包括4-APAA化合物和5-ASA化合物的组合治疗此类疾病。
• Mice with combined disruption of Gpx1 and Gpx2 genes have growth retardation, hypothermia, and colitis
  申请人：——

  公开号：US20020152482A1

  公开（公告）日：2002-10-17

  Disclosed is a transgenic knockout mouse whose genome has a homozygous disruption in its endogenous Gpx1 and Gpx2 genes, wherein the disruptions result in a decrease in GPX activity in the transgenic mice when compared to non transgenic mice of the same type. Methods for production of the mouse are presented. Also disclosed are cells derived from the transgenic knockout mouse. The mouse can be used in a method for identifying therapeutic agents for the treatment of an individual diagnosed with a metabolic disorder associated with a reduction or loss of expression of wild-type Gpx1 and Gpx2.

  本发明公开了一种转基因基因敲除小鼠，其基因组中的内源 Gpx1 和 Gpx2 基因被同源干扰，与同类型的非转基因小鼠相比，干扰导致转基因小鼠的 GPX 活性降低。本文还介绍了生产这种小鼠的方法。还公开了从转基因基因敲除小鼠中提取的细胞。该小鼠可用于鉴定治疗药物的方法，以治疗被诊断出患有与野生型 Gpx1 和 Gpx2 表达减少或丧失有关的代谢紊乱的个体。
• Mice with combined disruption of Gpx1 and Gpx2 genes have growth retardation, hypothermia, and colitis and provide a mouse model for cancer
  申请人：——

  公开号：US20030009776A1

  公开（公告）日：2003-01-09

  Disclosed is a transgenic knockout mouse whose genome has a homozygous disruption in its endogenous Gpx1 and Gpx2 genes, wherein the disruptions result in a decrease in GPX activity in the transgenic mice when compared to non transgenic mice of the same type. Methods for production of the mouse are presented. Also disclosed are cells derived from the transgenic knockout mouse. The invention further provides a mouse model for the disorders of ileitis, colitis,inflammatory bowel disease, ileal cancer and myeloleukemia. The mouse can be used in a method for identifying therapeutic agents for the treatment of an individual diagnosed with one or more of said disorders.

  本发明公开了一种转基因基因敲除小鼠，其基因组中的内源 Gpx1 和 Gpx2 基因被同源干扰，与同类型的非转基因小鼠相比，干扰导致转基因小鼠的 GPX 活性降低。本文还介绍了生产这种小鼠的方法。还公开了从转基因基因敲除小鼠中提取的细胞。本发明进一步提供了回肠炎、结肠炎、炎症性肠病、回肠癌和骨髓白血病等疾病的小鼠模型。该小鼠可用于鉴定治疗被诊断患有一种或多种上述疾病的个体的治疗药物的方法中。
• US1915429
  申请人：——

  公开号：——

  公开（公告）日：——
• SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF
  申请人：Advinus Therapeutics Limited

  公开号：EP2688890A1

  公开（公告）日：2014-01-29